Ellipticine derivatives, pharmaceutical compositions thereof, preparation methods and uses thereof

A technology of ellipticine and derivatives, applied in the field of medicine, can solve the problems of insensitivity and drug resistance of tumor stem cells, and achieve the effects of reduced toxicity and good anti-tumor application prospects.

Active Publication Date: 2021-07-02
INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
View PDF9 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Traditional chemotherapy drugs for tumor treatment have drug resistance problems, especially cancer stem cells are less sensitive

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ellipticine derivatives, pharmaceutical compositions thereof, preparation methods and uses thereof
  • Ellipticine derivatives, pharmaceutical compositions thereof, preparation methods and uses thereof
  • Ellipticine derivatives, pharmaceutical compositions thereof, preparation methods and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0084] 9,15-Dimethyl-15b,16-dihydroquinazolino[3',2':1,2]pyrido[4,3-b]carbazol-5(10H)-one

[0085] 9,15-Dimethyl-15b,16-dihydroquinazolino[3’,2’:1,2]pyrido[4,3-b]carbazol-5(10H)-one

[0086]

[0087] Dissolve 25 mg (0.1 mmol) of ellipticine and 27 mg (0.2 mmol) of 2-aminobenzoic acid in 3 ml of anhydrous N,N-dimethylformamide, and add 38 mg (0.2 mmol) of 1-ethyl-(3- Dimethylaminopropyl) carbodiimide hydrochloride (EDCI), reacted at room temperature for 5 hours, a yellow solid precipitated, and TLC monitoring showed that the reaction was complete. After concentration, the residue was extracted with dichloromethane (20 mL×3), and the combined organic phases were sequentially washed with saturated sodium bicarbonate solution, purified water and saturated sodium chloride solution, and dried overnight over anhydrous sodium sulfate. After evaporating dichloromethane, the obtained yellow solid was treated with absolute ethanol to obtain 20 mg of a yellow solid product with a yiel...

Embodiment 2

[0089] 3,9,15-Trimethyl-15b,16-dihydroquinazolino[3',2':1,2]pyrido[4,3-b]carbazol-5(10H)-on e

[0090] 3,9,15-Trimethyl-15b,16-dihydroquinazolino[3’,2’:1,2]pyrido[4,3-b]carbazol-5(10H)-one

[0091]

[0092] Dissolve 25 mg (0.1 mmol) of ellipticine and 30 mg (0.2 mmol) of 2-amino-5-methylbenzoic acid in 3 ml of anhydrous N,N-dimethylformamide, add 38 mg (0.2 mmol) of EDCI, and After 5 hours of reaction, a yellow solid precipitated out, and TLC monitoring showed that the reaction was complete. After concentration, the residue was extracted with dichloromethane (20 mL×3), and the combined organic phases were sequentially washed with saturated sodium bicarbonate solution, purified water and saturated sodium chloride solution, and dried overnight over anhydrous sodium sulfate. After evaporating dichloromethane, the obtained yellow solid was treated with absolute ethanol to obtain 24 mg of a yellow solid product with a yield of 63.3%. 1 H NMR (500MHz, DMSO-d 6)δ11.30(s,1H,N-H)...

Embodiment 3

[0094] 4,9,15-Trimethyl-15b,16-dihydroquinazolino[3',2':1,2]pyrido[4,3-b]carbazol-5(10H)-one

[0095] 4,9,15-Trimethyl-15b,16-dihydroquinazolino[3’,2’:1,2]pyrido[4,3-b]carbazol-5(10H)-one

[0096]

[0097] Dissolve 25 mg (0.1 mmol) of ellipticine and 30 mg (0.2 mmol) of 2-amino-6-methylbenzoic acid in 3 ml of anhydrous N,N-dimethylformamide, add 38 mg (0.2 mmol) of EDCI, and After 5 hours of reaction, a yellow solid precipitated out, and TLC monitoring showed that the reaction was complete. After concentration, the residue was extracted with dichloromethane (20 mL×3), and the combined organic phases were sequentially washed with saturated sodium bicarbonate solution, purified water and saturated sodium chloride solution, and dried overnight over anhydrous sodium sulfate. After evaporating dichloromethane, the obtained yellow solid was treated with absolute ethanol to obtain 17 mg of a yellow solid product with a yield of 44.9%. 1 H NMR (500MHz, DMSO-d 6 )δ11.27(s, 1H, N-...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to formula (I, II, III, IV) ellipticine derivatives or pharmaceutically acceptable salts thereof, the derivatives have excellent antitumor activity, small side effects, low toxicity and / or high solubility in water, They can be used as antitumor agents and antiviral agents, and the present invention relates to the compounds and their preparation methods, pharmaceutical compositions and applications.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a new class of ellipticine derivatives, a pharmaceutical composition containing them, and their application in the preparation of antitumor and antiviral drugs. Background technique [0002] In the past 30 years, although various diagnosis and treatment levels of tumors have been significantly improved, the morbidity and mortality of tumors are still increasing worldwide. According to the forecast of the World Health Organization (WHO), by 2020, the number of cancer cases worldwide will increase to 20 million, and the death toll will reach 12 million. [1] . In 2015, 8.2 million people died of cancer worldwide, including 2.8 million in China. Now 7,500 people die of cancer every day in China. China has the highest number of cancer deaths in the world. In China, the prevalence of cancer is 280 per 100,000, showing a trend of rapid growth year by year [2] . The ma...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C07D471/14C07D495/22A61K31/519A61P35/00A61P35/02A61P31/16A61P31/22A61P31/14A61P31/20
CPCY02A50/30
Inventor 潘显道李燕林菁菁沈珑瑛杨亚军郑稳生
Owner INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap